Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 17/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154178 | 0.83 | PTGS2 (0.41) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6153876 | 0.82 | PTGS2 (0.37) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6153110 | 0.82 | PTGS2 (0.40) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6152870 | 0.80 | CYP4F2 (0.42) | PTGS2PTGS1ALOX5 | |
| SCHEMBL7564634 | 0.79 | PTGS2 (0.40) | PTGS2PTGS1ALOX5NOTUM | |
| SCHEMBL5736806 | 0.79 | CYP26A1 (0.40) | — | |
| SCHEMBL6153543 | 0.79 | PTGS1 (0.38) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6153167 | 0.78 | PTGS2 (0.39) | PTGS2PTGS1ALOX5 | |
| SCHEMBL2489432 | 0.78 | AHR (0.38) | PTGS2PTGS1ALOX5NOTUM | |
| SCHEMBL6154436 | 0.77 | PTGS2 (0.37) | PTGS2PTGS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499604-A1 | DIHYDROBENZOFURAN AND DIHYDROBENZOTHIOPHENE 2,4-PENTAIDENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | Allergan, Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6720423-B2 | SKIN RELATED DISEASES; PROMOTE THE EXPRESSION OF OR BIND TO RECEPTORS BELONGING TO THE STEROID OR THYROID RECEPTOR SUPERFAMILY. | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003093257-A1 | DIHYDROBENZOFURAN AND DIHYDROBENZOTHIOPHENE 2,4-PENTAIDENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1228055-A1 | DIHYDROAMINOBENZO[B]- AND [C]FURANS AS RETINOID-LIKE AGENTS | Allergan Sales, Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001012618-A1 | DIHYDROAMINOBENZO[B]- AND [C]FURANS AS RETINOID-LIKE AGENTS | ALLERGAN SALES, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-6093838-A | FOR TREATING SKIN-RELATED DISEASES, INCLUDING ACTINIC KERATOSES, ARSENIC KERATOSES, ECZEMA | ALLERGAN SALES, INC. (US) | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | RXRB, RXRA, RXRG | PTGS2 1241/4885PTGS1 973/4885ALOX5 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.